不同剂量洛伐他汀治疗冠心病伴高脂血症患者的疗效分析

Efficacy of different dosage of Lovastatin in patients with coronary disease combined hyperlipidemia

目的:探讨不同剂量洛伐他汀对冠心病并发高脂血症患者的血脂及C-反应蛋白(CRP)的影响。方法:选择冠心病并发高脂血症患者120例,随机分为两组,A组给予洛伐他汀20mg/d,B组给予洛伐他汀40mg/d,两组分别在治疗前及治疗后4周和8周检测血清胆固醇(TC)、低密度脂蛋白(LDL-C)、三酰甘油(TG)、高密度脂蛋白(HDL-C)和CRP的水平及肌酸磷酸激酶(CK),比较不同剂量洛伐他汀的疗效及安全性。结果:洛伐他汀治疗4周后,可有效降低冠心病并发高脂血症患者的TC、TG、LDL-C以及CRP水平(P<0.01或P<0.05),且B组优于A组(P<0.05)。结论:洛伐他汀强化剂量治疗冠心病伴高血脂症疗效明显优于常规剂量,且两者均具有良好的安全性。

Objective：To observe the efficacy of the different dosage of Lovastatin on blood lipid level and reactive protein in patients with coronary heart disease combined hyperlipidemia.Methods：120 patients with coronary disease combined hyperlipidemia were randomly divided into two groups,group A took Lovastatin 20 mg,group B took Lovastatin 40 mg.The patients＇ TC,LDL-C,TG,HDL-C,CRP and CK were detected after 4 weeks and 8 weeks.The efficacy and safety of different doses of Lovastatin were compared.Results：The levels of TC,TG,LDL-C and CRP were reduced significantly by Lovastatin in patients after 4 weeks（P〈0.01 or P〈0.05）,group B was better than group A（P〈0.05）.Conclusion：Large dosage of Lovastatin is better than routine dosage in the treatment of coronary heart disease combined hyperlipidemia and both methods have good safety.